Title

0016

11/21/2025

by **ofira zloto** in **Research Infrastructure Program FY26**

id. 52402101

[redacted]

Original Submission

11/21/2025

Score	n/a
Applicant Name (Organization)	Other
OTHER-Applicant Name (Organization)	The ARC Port Boston Soft Landing Pad (Currently in the process to register as a MA non-for profit company).
Applicant City/Town	Boston, Massachusetts
Please indicate if this proposal is for a research institution/academic medical center core facility or an incubator/accelerator expansion.	Incubator / Accelerator
Principal Investigator Name	Yonatan Keschner
Job Position Title	CEO, ARC Port Boston - ARC's Soft Landing Pad Accelerator in Boston
Email	ykeschner@arcinnovation.org
Phone Number	+15162419177
Co-Applicants	**Coapplicants.xlsx**
Name of Authorized Representative	Yonatan Keschner
Title of Authorized Representative	CEO The ARC Port Boston, Soft Landing Pad
Email of Authorized Representative	ykeschner@arcinnovation.org

Have you been awarded an MLSC grant in the past?	No
Title of Project	ARC Port Boston, ARC's Soft Landing Pad Accelerator in Boston
If applicable, what fields can be advanced using this resource? Please choose up to three options.	Cardiology/ Cardiovascular Research Neuroscience Other
Other-Disease(s) and Condition(s)	Other- All specialties in medicine, depending on the startups selected for the accelerator. We are now in the process of interviewing the companies that will be part of the first cohort. Please find attached and the link for the call for application with the timelines at: https://arcinnovation.org/ecosystem/boston-soft-landing-pad-accelerator/
If applicable, what modality/modalities does your project primarily employ? Please choose up to three options.	Digital Health Data Science Medical Device
What are tools and techniques used in your project? Please choose up to three options.	Software & Algorithms AI/ML/Deep Learning Other
Other- Tools and Techniques	Different type of technologies, depending on the startups selected for the accelerator.
Project Narrative	

1. Elevator Pitch	ARC (Accelerate, Redesign, Collaborate) Innovation, founded in 2019 by Sheba Medical Center,Israel's largest hospital and a top 10 global healthcare institution, is dedicated to transforming healthcare through collaboration and entrepreneurship.ARC has grown into a worldwide ecosystem, bringing together leading healthcare systems, strategic industry partners, and over 120 innovative startups. The ARC Boston Soft Landing Pad ("ARC Boston") designed to accelerate international healthcare innovation in Massachusetts by providing early-stage companies with the resources, expertise, and infrastructure needed to develop, validate, and scale breakthrough technologies in the U.S. market.Through access to Massachusetts' advanced clinical, academic, and commercial environment, ARC Boston will support startups in advancing solutions that meaningfully improve patient outcomes and prognosis. MLSC funding is essential to establishing the collaborative infrastructure required to launch ARC Boston. Each six-month cohort takes place on-site in Boston and includes dedicated workspace at no cost, reflecting our mission to support startups entering the U.S. healthcare system.ARC Boston provides in-house expertise and guidance from EIRs across regulatory strategy, reimbursement, go-to-market planning, business models, pitch refinement, research and pilot design, and investor preparation. We also connect companies with subject-matter experts, key opinion leaders, and a broad network of partners from academic medical centers, community hospitals, and industry.
2. Please describe the capability of the team to execute on, and sustain, the project.	ARC (Accelerate, Redesign, Collaborate) Innovation, founded in 2019 by Sheba Medical Center, Israel's largest hospital and a top 10 global healthcare institution, is dedicated to transforming healthcare through collaboration and entrepreneurship. ARC has grown into a worldwide ecosystem, bringing together leading healthcare systems, strategic industry partners, and over 120 innovative startups. The ARC Boston Soft Landing Pad ("ARC Boston") designed to accelerate international healthcare innovation in Massachusetts by providing early-stage companies with the resources, expertise, and infrastructure needed to develop, validate, and scale breakthrough technologies in the U.S. market. Through access to Massachusetts' advanced clinical, academic, and commercial environment, ARC Boston will support startups in advancing solutions that meaningfully improve patient outcomes and prognosis. MLSC funding is essential to establishing the collaborative infrastructure required to launch ARC Boston.
3. 2-Page CV/Biosketch Upload **ARC_Bios_Combined.pdf**	

4. Please list requested equipment and explain why each are required for the project.	Space and Renovation • Renovate the selected downtown Boston space—now in the final stages of evaluation—to create collaborative areas, conference rooms, modular offices, and specialized dry/prototyping labs tailored to the needs of our incoming startups. Attached are the price quotes for the two finalist locations under consideration. Technology and Equipment • Acquire advanced prototyping tools (3D printers, laser cutters, CNC machines). • Establish high-performance IT infrastructure for AI, analytics, and secure data storage. • Add telemedicine and remote-monitoring equipment for digital health development. • Install modern AV systems for hybrid meetings and global collaboration. Hardware equipment, including computers, printers, screens, keyboards, mice. Digital and Software Tools • Implement secure platforms for productivity tools (Microsoft 365), data management, decentralized clinical trials, and collaborative work. • License specialized software for regulatory submissions, simulation, analysis, and design • Cloud storage Testing and Validation Facilities • Create clinical simulation suites for realistic testing of healthcare technologies. • Establish user-testing labs for usability studies, focus groups, and pilot evaluations. Workspace Amenities • Provide coworking areas, modular workstations, meeting rooms, and flexible event spaces. • Include administrative space and secure storage to support daily operations. Security and Compliance • Install secure, healthcare-grade data infrastructure. • Integrate compliance-ready systems including HIPAA-aligned tools for handling clinical data.
5. Who will maintain, schedule, and manage the equipment?	The equipment will be managed by ARC Boston's facilities and operations team. A dedicated operations manager will oversee maintenance, vendor servicing, and MA regulatory compliance. IT staff will manage installation, calibration, cybersecurity, and software updates for specialized equipment. Scheduling and user access will be coordinated through ARC Boston's centralized digital system.

6. When would the equipment/infrastructure be up and running for public use?	The equipment and infrastructure will be fully operational by March 2026, aligned with the start of the incoming startup cohort March 2nd, 2026.
7a. What is the potential for the investment to provide value and development opportunities to emerging companies?	The proposed ARC Boston Soft Landing Pad will provide high-value development opportunities for emerging life science companies by offering a comprehensive environment that integrates clinical access, regulatory navigation, technical validation, and market entry strategies. Startups entering the program will gain structured support across all stages of growth early prototyping, preclinical development, clinical collaborations, and commercialization. By leveraging the global ARC Innovation Network and Sheba Medical Center's world class clinical and research ecosystem, companies will have unique access to physician innovators, patient populations, and real-world clinical settings. This access significantly accelerates evidence generation, usability testing, and partnerships with major academic hospitals. Additionally, participating companies will receive tailored mentorship from leaders in AI, digital health, device development, and biotech. The program will also provide introductions to Boston based investors, venture funds, industry partners, payors, and health systemsn key stakeholders required for successful scale up in the U.S. The investment will therefore create a high impact platform that reduces time to market, lowers early operational barriers, and expands opportunities for emerging companies to build sustainable, competitive ventures in Massachusetts.

7b. Please outline the potential to fill a gap or accelerate growth in a particular sub-cluster of the life sciences.	The program directly addresses a structured soft landing pathway for globally developed health tech, AI based, and clinical stage technologies seeking U.S. entry. This program is designed to help international companies navigate the clinical, regulatory, and commercialization steps required to establish operations in the U.S. healthcare market. ARC Boston focuses on three rapidly expanding sub clusters: AI and Data Driven Medicine (diagnostics, imaging, predictive analytics) Digital Health and Care Delivery Innovation MedTech and Clinical Grade Devices These sectors experience strong global innovation but often face barriers when adapting to U.S. workflows, payer systems, and FDA expectations. The Soft Landing Pad provides structured clinical validation opportunities through Sheba and its U.S. partners, enabling companies to rapidly generate proof points needed for pilots, FDA submissions, and provider adoption. By strengthening the bridge between international R&D engines and the Massachusetts life sciences community, the program accelerates market growth, supports the local workforce, and enhances the competitiveness of these sub clusters.
7c. Please demonstrate the market demand for such incubator/accelerator resources and how the requested resource will differentiate itself from existing resources.	Demand for specialized soft landing support in Massachusetts is exceptionally high. Each year, hundreds of global health-tech and life-sciences startups seek entry into the U.S. market but lack the clinical partnerships, regulatory expertise, and local infrastructure necessary to scale. The proposed Soft Landing Pad differentiates itself through: • Direct access to clinical environments, physicians, and real-world data through Sheba Medical Center and its 20+ partner hospitals. • A structured regulatory and reimbursement pathway, tailored to international founders unfamiliar with U.S. systems. • A global innovation network spanning Israel, Europe, and North America, enabling multi-center validation and expansion. • Hands on mentorship from clinician-innovators experienced in AI, MedTech, and digital health adoption.

7d. Please outline the qualifications, experience and expertise of the Applicant to create, manage, and sustain an incubator/accelerator.	ARC Boston is uniquely qualified to create, manage, and sustain this accelerator due to its deep experience operating innovation programs across Sheba Medical Center ranked among the world's leading smart hospitals and its established Soft Landing Pad model already serving dozens of companies globally. As part of ARC Innovation at Sheba, the Boston team brings robust operational capabilities in running accelerators, facilitating clinical trials, enabling regulatory strategy, and supporting international companies through U.S. market entry. The organization has a proven track record supporting more than 120 startups, including AI, MedTech, digital health, and biotech companies that have successfully secured FDA clearances, raised significant investments, and launched commercial partnerships. ARC's leadership includes seasoned clinical experts, healthcare executives, entrepreneurs, and investors with decades of cumulative experience in company building, clinical research, and technology adoption. The team's deep integration with hospitals in Massachusetts and Israel ensures strong access to clinical mentors, early adopters, and pilot sites. This established infrastructure combined with Boston based operational staff and Sheba's extensive innovation ecosystem positions ARC Boston as an experienced and capable applicant to build and sustain a high-impact accelerator.
7e. Please detail your plans to recruit companies with diverse/underrepresented leadership.	ARC Boston is committed to advancing diversity, equity, and inclusion across the life-sciences ecosystem. The program will actively recruit companies led by women, immigrants, founders from low representation geographies, and leaders from communities traditionally underrepresented in biotech and digital health. Sheba Medical Center already houses award winning leadership development programs for women physicians and innovators, giving the ARC team strong experience in supporting diverse leadership at scale. This commitment will extend to ARC Boston, ensuring that the accelerator not only identifies but actively nurtures companies that broaden representation across the Massachusetts life-sciences community.
Uploaded Financial and Letter Documents	
8a. Total Amount of MLSC Funding Requested	3000000

8b. Breakdown of Expenditures: MLSC

MLSC Budget.xlsx

8c. Vendor Quotations of Capital Equipment over $100,000

ALL_PROPOSALS_COMBINED.pdf

9a. Total Amount of Funding Committed by Non-MLSC Sources (Academic + Industry budgets)	5000000

9b. Breakdown of Expenditures: Academic Contributions

Academic Budget.xlsx

9c. Breakdown of Expenditures: Industry Contributions (Optional)

Industry Budget.xlsx

10. Letters of Commitment from Funding Sources

Letter_of_Commitment_Sheba_ARC.pdf

Massachusetts Ecosystem Development

11. Value to the Community	ARC Port Boston will bring next-generation healthcare technologies into the Commonwealth, ensuring their benefits extend well beyond the Applicant institution and into Massachusetts' broader life sciences community.By establishing a shared, high-performance environment, the accelerator will provide clinical validation, commercial guidance, mentorship, and real-world pilots for early-stage companies.This will accelerate the development of digital health tools, AI-driven diagnostics, and medical device innovations that improve patient care across Massachusetts. ARC Boston will also strengthen healthcare equity statewide.Community hospitals, outpatient centers, and clinical practices - particularly those outside major academic hubs, will gain access to innovation activities and new technologies. Advanced hybrid audiovisual systems will enable remote participation in training, design sessions, workshops, and collaborative research, expanding opportunities for clinicians and researchers in underserved and resource-limited regions. The initiative will also contribute to job creation across multiple sectors as ARC Boston accelerates a new pipeline of health-tech companies into Massachusetts.The accelerator will generate roles in AI engineering, data and medical science, product development, and computational infrastructure, alongside business, operational, and administrative positions essential to the program's success. Beyond these immediate roles, ARC Boston will strengthen the state's workforce development ecosystem through hands-on training, entrepreneurship programs, and real-world innovation experiences for students,fellows, and early-career professionals.This will expand opportunities for local talent and enhance the Commonwealth's ability to attract and retain highly skilled innovators. Overall,ARC Boston will fortify Massachusetts' innovation ecosystem, expand equitable access to cutting-edge technologies, support job growth, improve community health outcomes,and reinforce the Commonwealth's leadership in life sciences and digital health innovation.

12. If relevant, please upload letters of interest from 3-5 academic researchers with a brief (3 sentence) description of a potential project using the equipment requested.	

13. Please upload letters of interest from 3-5 industry partners with a brief (3 sentence) description of a potential project using the equipment/space requested.

Letters_of_Interest_-_Signed_decleration_1.pdf

14. Project Outcomes and Impact (What does “success” look like and how will it be measured?)	Success for ARC Boston will be defined by the measurable advancement of early-stage life science and digital health startups. By their ability to enter and compete in the U.S. market, and their impact on patient care and public health. The shared innovation infrastructure and mentoring of ARC Boston will enable startups to accelerate product development, achieve stronger clinical validation, bring new solutions to patients faster, create new jobs in MA, hire local talents, encourage and create new partnerships. ARC Boston aims to support startups whose technologies offer meaningful improvements in diagnosis, treatment, and patient outcomes. Success will be demonstrated by innovations that bring hope to patients, improve quality of life and expand access to care. Success indicators will include the number of new clinical collaborations, pilot studies, and real-world deployments initiated through the accelerator. From an economic perspective, success will be measured by the growth of the participating startups, including revenue generation, development of strong and sustainable business plans, ability to secure funding from leading global investment funds, achievement of profitability, and the creation of new high-quality jobs. In conclusion, ARC Boston impact will be seen in a thriving ecosystem with a pipeline of companies that improve patient care and strengthening the state’s innovation economy, demonstrating that scientific advancement, commercial success, and community benefit can grow together.

Authorized Representative Signature

IMG-20251121-WA0005_1.jpg

Authorized Signatory Job Position Title	CEO, ARC Port Boston - ARC’s Soft Landing Pad Accelerator in Boston
How did you hear about the program?	Program Manager / MLSC Staff

Please select for the Principal Investigator to receive email notices and updates from the MLSC newsletter.	unchecked

We look forward to reviewing your application and working together to advance life sciences research capabilities in Massachusetts. If you have any questions or need assistance, please contact our team at ResearchInfrastructure@masslifesciences.com.

November 20, 2025

Letters of Interest from Industry Partners-

ARC Boston – Soft Landing Pad Accelerator

To Whom It May Concern,

As part of the MLSC requirement for Letters of Interest from industry partners, we wish to clarify that the selection process for the first cohort of companies participating in the ARC Boston Soft Landing Pad Accelerator is currently underway. Because final selections have not yet been completed, the formal Letters of Interest from the participating companies will be submitted once the cohort is finalized.

ARC Global and ARC Boston have formally launched the Call for Applications for companies seeking to join the Soft Landing Pad program (attached) .

At this stage, we are conducting the screening and evaluation process, and by the end of 2025, the selected companies will be notified of their acceptance. Immediately thereafter, we will submit the required Letters of Interest from the confirmed participants, in accordance with MLSC guidelines.

We appreciate the MLSC's understanding and remain committed to providing all required documentation as the selection process progresses.

Sincerely,
Orli Biger
Executive Director, ARC USA
ARC Global Network

November 20, 2025

Letter of Commitment- Sheba Medical Center and ARC Global
Commitment to ARC Port Boston – Soft Landing Pad

To whom it may concern,

On behalf of Sheba Medical Center and ARC Global, I am pleased to submit this Letter of Commitment in support of the MLSC Research Infrastructure Grant proposal for the ARC Port Boston Soft Landing Pad accelerator.

Sheba Medical Center and ARC Global recognize the strategic importance of establishing a Boston-based platform that will facilitate clinical, academic, and technological collaboration with the Massachusetts life sciences community. The proposed accelerator directly aligns with our institutional mission to advance healthcare innovation and accelerate the development and adoption of impactful technologies.

Financial Commitment

Sheba Medical Center and ARC Global hereby commit a total of:

USD $5,000,000 (five million dollars) to support the successful implementation and operation of the ARC Port Boston Soft Landing Pad. This commitment includes financial investment, personnel time, access to clinical and research environments, and institutional resources required to ensure the project's success.

Importance to Our Organizations

The ARC Port Boston initiative is of strategic importance to both Sheba Medical Center and ARC Global. It will:

- Strengthen our long-standing partnership with the life sciences ecosystem of Massachusetts.
- Expand our ability to bring cutting-edge health-tech, AI, and digital medicine solutions to the U.S. market.

- Allow high-potential startups to enter Massachusetts with clinical, regulatory, academic, and commercialization support from both ARC Global and local partners.
- Foster joint research, clinical validation, and technology deployment programs that benefit both healthcare systems.
- Drive economic growth and job creation in the Commonwealth through development of transformative healthcare startups

Commitment to Project Success

Sheba Medical Center and ARC Global affirm their full commitment to this project and will allocate the resources necessary to ensure its successful launch, operation, and long-term impact.

We look forward to partnering with the Massachusetts Life Sciences Center on this important initiative and maximizing its impact on the Massachusetts ecosystem and global healthcare innovation.

Sincerely,

Eyal Zimlichman, MD, MSC, MHCM
Chief Transformation, Innovation and AI Officer at Sheba Medical Center
Director and Founder of ARC Innovation
Future of Health (FOH), Co-Chairman

	Name	Role	Organization	Email	Phone
1	Orli Biger	CEO, ARC US	American Friends of Sheba	Orli.biger@arcinnovation.org	[redacted]
2	Prof. Ofira Zloto	Head of Research and Academic Partnershi	ARC Port Boston	[redacted]	[redacted]
3					
4					
5					
6					
7					
8					
9					
10					

Name: Yonatan G. Keschner, MD, MHCM

Position Title: CEO, ARC Port Boston; Executive Advisor, Sheba ARC; Instructor in Emergency Medicine, Harvard Medical School; Emergency Physician, Brigham and Women's Hospital.

Personal Statement

I am an emergency physician, healthcare innovation leader, and CEO of ARC Port Boston, the U.S. "soft-landing pad" of Sheba Medical Center's Global ARC (Accelerate, Redesign, Collaborate) network. Launched with Governor Healey's announcement in May 2025, ARC Port Boston supports commercialization for more than 120 health-tech companies and engages a growing global pipeline from ARC partner sites in Los Angeles, Singapore, Belgium, Germany, New Zealand, Australia, and the United Kingdom. My background spans clinical care, digital health innovation, and building accelerator programs that guide startups through clinical validation and trials, regulatory and reimbursement strategy, and U.S. market entry. I previously led a federally funded HealthTech accelerator at Mass General Brigham and the Advanced Regenerative Manufacturing Institute, accelerating 59 international startups into the U.S. market while advancing cross-border innovation ecosystems. Academically, I serve as a principal investigator, have secured more than $2.5M in grant funding—including federal sub-awards—published peer-reviewed research in healthcare AI, clinical operations, and patient and provider experience, and delivered over 75 invited talks across national and international forums.

Positions, Scientific Appointments & Honors

- 2025–Present: CEO, ARC Port Boston (ARC Global – Sheba Medical Center)
- 2025–Present: Executive Advisor, ARC Sheba and ARC Global
- 2024-Present: Affiliate Faculty, MGB Clinical Informatics Fellowship (ACGME accredited)
- 2023–2025: Director and Co-PI, HealthTech Hub at ARMI, MGB Innovations
- 2020–2023: Director, MGB Springboard Studio
- 2020–2023: Digital Health Lead, Strategic Collaboration Unit, MGB Emergency Medicine
- 2022–Present: Instructor, Emergency Medicine, Harvard Medical School
- 2020–Present: Emergency Medicine Faculty, Brigham and Women's Hospital
- 2020–2022: Administration and Innovation Fellow, Mass General Brigham

Selected Honors

- 2025 – Innovation Award, MGB
- 2023 – Nathaniel Bowditch Award – Value Based Care, MGH
- 2023 – Physicians Choice Award – Home Hospital, ACEP
- 2022 – iSolve Award, MGH
- 2022 – Top Single Practice Innovation Award, HaHUG
- 2019 – Top Innovation Pitch, MGH
- 2016 – Distinction in Research, Einstein Medical School

Selected Contributions to Science

1. Digital Health & Clinical Decision Support — Led or co-led multiple clinical innovations and research trials of AI tools in the Emergency Department, including digital triage, virtual care and home hospital systems, and AI-guided ultrasound cardiac assessments. Published peer-reviewed work on clinical decision support, digital triage, and patient experience technologies.
2. Innovation Ecosystem Development — Architect of the Boston–Israel health innovation corridor, bridging MGB, Sheba ARC, and the Commonwealth of Massachusetts to accelerate international health-tech companies into the U.S. healthcare system.
3. Translational Research — Inventor, Co-PI and Investigator on NIH and DHHS-funded projects involving AI ultrasound cardiac assessments, AI pregnancy-risk modeling, IBD photobiomodulation technology, AI-based

home-hospital triage screening tools, and patient and provider experience interventions – including use of virtual windows in the emergency room.

Selected Publications

- Lai L, Wittbold KA, Dadabhoy FZ, Sato R, Landman AB, Schwamm LH, He S, Patel R, Wei N, Zuccotti G, Lennes IT, Medina D, Sequist TD, Bomba G, **Keschner YG**, Zhang HM. Digital Triage: Novel strategies for population health management in response to the COVID-19 pandemic. Healthc (Amst). 2020 Dec.
- Ouchi K, Liu S, Tonellato D, **Keschner YG**, Kennedy M, Levine DM. Home Hospital as a Disposition for Older Adults from the Emergency Department: Benefits and opportunities. J Am Coll Emerg Physicians Open. 2021 Aug.
- Chu A, **Keschner YG,** Lai L, Baugh J, Baugh CW, Biddinger P, Raja A, Isselbacher E, Conley J. An Educational Mobile App Helps Trainees Manage Bedside Emergencies. AEM Educucation and Training. 2021 Sep.
- **Keschner YG**, Hasdianda MA, Miyawaki S, Baugh CW, Chen PC, Hipeng MZ, Landman AB, Chai PR. Assessing Patient Experience and Orientation in the Emergency Department with Virtual Windows. HICSS. 2022 Jan.
- Goldfine CE, Knapp A, Goodman GR, Hasdianda MA, Huang H, Marshall AD, **Keschner YG**, Carreiro S, Jambaulikar GD, Chai PR. Media and Technology Usage and Attitudes in Emergency Medicine Patients. Frontiers in Digital Health. 2022 Oct.
- **Keschner YG**, Raja A, Margolin, J, Zheng H, Olson K. Assessing the experience and effectiveness in the emergency department of a novel anti-fog polymer in protective eyewear. BMJ Innovations. Published Online First. 2022 Nov.
- Goldsmith A, Duggan N, **Keschner YG**, Baymon DE, Luo A, Nagdev A, Kapur T, Calplan S, Meguerdichian D, Baugh CW. National Cost Savings From Use of Artificial Intelligence Guided Echocardiography in the Assessment of Intermediate-Risk Patients With Syncope in the Emergency Department. JACEP Open. 2025 Jun.

Selected Grants

- 2019-2020 – Co-PI: Study on Patient Acceptability and Experience with Virtual Windows in the Emergency Department (BWH BCRISP), **$50,000**
- 2020-2022 – Co-PI: RCT on the Effectiveness of an Anti-fog Polymer Coating in Protective Eyewear (Kraton Polymer LLC), **$100,000**
- 2021-2023 – Co-PI: Development and Assessment of Peer-Recognition Platform for Healthcare Providers (BWH BCRISP, BWH BWell, MGPO), **$81,000**
- 2024–2025 – Co-PI: HealthTech Hub Accelerator for International Startups at ARMI/MGB (DHHS-ASPR), **$2,238,277**
- 2024–Present – Co-Investigator: NIH Lung Ultrasound Deep Learning Project
- 2025–Present – Co-PI: Evaluating Artificial-Intelligence-guided Cardiac Ultrasound in the Emergency Department (UltraSight), **$195,951**
- 2025-Present - Co-I: Photobiomodulation Therapy for IBD Utilizing a PhotoPill (DHHS, Sub-Award), **$74,346**
- 2025-Present: Co-PI: Validation of an AI-Based High-Risk Pregnancy Model (DHHS, Sub-Award), **$33,750**

Education & Training

- BS , Ecological Technology and Design, University of Maryland, Honors College, 2010
- MD, Albert Einstein College of Medicine, 2016
- Emergency Medicine Residency, MGH/BWH, 2016–2020
- Fellowship, EM Administration & Innovation, MGB, 2020–2022
- MS, Healthcare Management, Harvard T.H. Chan School of Public Health, 2022

Orli Biger, MHA&PH, MBA

Chief Executive Officer, ARC US

ARC Innovation

American Friends of Sheba Medical Center

Orli Biger is the CEO of ARC US, where she focuses on healthcare innovation and establishing an innovation and simulation center in Jersey City, New Jersey, aimed at the future of healthcare, as well as a soft-landing pad for ARC's international startups, in MA.

Orli joined ARC, the innovation platform of Sheba Medical Center, in May 2022 as the Chief Business Officer, where she led strategic partnerships and expanded ARC's network of international partners, including medical centers, industry partners, academic institutions, government offices, and startups.

Since relocating to the US in July 2022, Orli has also led ARC Global, overseeing global initiatives and consulting services, collaborating with international medical centers to build ARC sites, and partnering with Deloitte to expand ARC's global network.

With over 18 years of experience in the pharmaceutical industry, Orli has held roles in marketing, sales, commercialization, and strategy across various therapeutic areas in international companies such as Teva Pharmaceutical Industries, Pfizer, Janssen, Johnson & Johnson, and Merck.

Orli holds an MBA in Healthcare Innovation from Reichman University, a master's degree in health administration and public health from Bar Ilan University, and a B.Sc. in Bio-Medicine from Tel-Aviv University. She was a teaching assistant for two MBA courses on "Redesign Healthcare" and "Innovation in Healthcare Services" at Reichman University.

Ofira Zloto, M.D. – Professional & Research Bio

Dr. Ofira Zloto, M.D., Clinical Associate Professor of Ophthalmology at Tel Aviv University, is a dual-fellowship trained ophthalmologist specializing in oculoplastic surgery and pediatric ophthalmology, with an extensive research portfolio spanning clinical innovation, population-based studies, and artificial intelligence in ophthalmology. She serves as a senior oculoplastic and pediatric ophthalmic surgeon at the Goldschleger Eye Institute, Sheba Medical Center, Israel's largest academic medical center, where she also leads several strategic research and education initiatives.

Professional and Academic Background

Dr. Zloto completed her medical degree at the Hebrew University–Hadassah Medical School with multiple academic distinctions, including the Hoffman Prize, the Best M.D. Thesis Award, and a clinical excellence fellowship at Albert Einstein College of Medicine (NYC). She completed her ophthalmology residency at Sheba Medical Center, followed by advanced subspecialty training in Ocular Oncology (Institut Curie, Paris), Pediatric Ophthalmology (Creteil, France), and Oculoplastic Surgery (Moorfields Eye Hospital, London).

At Sheba Medical Center, she serves as a senior consultant surgeon in both the Oculoplastic and Pediatric Ophthalmology units and founded the center's first Eye Movement Disorders Clinic, a multidisciplinary clinic bridging neurology and ophthalmology. In parallel, she holds multiple national leadership roles, including Head of the Stage II Ophthalmology Board Examination in Israel and Deputy Editor of the Israeli Journal of Ophthalmology.

In 2025–2026 she will join Harvard T.H. Chan School of Public Health for the Executive Leadership in Health Care program, integrating her clinical, research, and innovation work into advanced health-systems leadership.

Research Focus and Scientific Impact

Across her career, Dr. Zloto has established a robust research portfolio of over 120 peer-reviewed publications, spanning high-impact journals including Ophthalmology, AJO, Eye, BJO, IOVS, and Scientific Reports. Her work ranges from basic science and translational research to international multicenter collaborations and AI-driven clinical analytics.

Research Leadership & Mentorship

Dr. Zloto is deeply engaged in developing Israel's next generation of clinician-scientists. She has mentored numerous M.D. students, Ph.D. candidates, and research fellows across projects in oncology, pediatric ophthalmology, and AI in oculoplastics. Many of her mentees have won research awards and presented at international meetings.

Grant Funding

She has served as Principal Investigator on multiple competitive grants, including:

- Alrov Foundation Grants

- Martie Foundation Grants

- Ministry of Health Digital Health Grant

Awards and Honors (Selected)

• Talpiot Prize for Excellence in Medicine & Research

• Stein Award for Distinguished Researcher in Ophthalmology

• Alrov Prize for Excellence in Research (multiple years)

• ARVO International Travel Grant

• Best Resident Award

• Hoffman Prize and Best M.D. Thesis Award

International Involvement & Scientific Community

Dr. Zloto is an active speaker and organizer at leading ophthalmic meetings, including ESOPRS, ASOPRS, ARVO, ISVER, and IMCAS. She is a member of ARVO, ESOPRS, ASOPRS, and the Israeli Ophthalmology Society.

Summary

Dr. Ofira Zloto is an accomplished clinician-scientist whose work sits at the intersection of oculoplastic surgery, pediatric ophthalmology, neuro-ophthalmology, and AI-driven innovation. Her research volume, international collaborations, leadership roles, and translational contributions position her as a leading figure shaping the future of ophthalmic care and surgical innovation.

Academic Contributions for Project

Category Options: Equipment, Supplies/Reagents, Software, Renovation/Construction, Salaries, Indirects, F

Total Academic Contribution $ 2,000,000.00

*Do not include $ or commas in FY Estimated Contribution column

Academic Organization Name	Description of Contribution	Category (See Category Options)	Estimated Monetary Value of Contribution
Sheba Medical Center	Faculty effort (PI , research integration, clinical e	Salaries	$ 500,000.00
Sheba Medical Center	Renovation and preparation of facilities required	Renovation/Construction	$ 300,000.00
Sheba Medical Center	Software licenses for prototyping, analytics, and	Software	$ 500,000.00
Sheba Medical Center	Facility access, research space, utilities, and ope	Facility Costs	$ 200,000.00
Sheba Medical Center	Additional institutional support relevant to projec	Other	$ 250,000.00
Sheba Medical Center	ARC Global team- support and guidenss	Human resources	$ 250,000.00
		*ARC Sheba commits to providing a total of $5 million over a	
Total Contribution			$ 2,000,000.00

ı five-year period. The costs, targets, and

MLSC Expenses for Project

Category Options: Equipment, Supplies/Reagents, Software License, Renovation/Construction

Total MLSC Contribution	**$**	**2,960,980.00**
FY27 (7/1/26 – 6/30/27)	$	619,980.00
FY28 (7/1/27 – 6/30/28)	$	1,792,000.00
FY29 (7/1/28 – 6/30/29)	$	549,000.00

*Do not include $ or commas in FY Estimated Cost column

Vendor	Equipment / Item Description	Category (See Category Options)	FY27 Estimated Cost
Microsoft Azure, AWS	A HIPAA-aligned research computing environment providing:	HIPAA	$ 120,000.00
	secure VPC and network isolation, role base acess control, full encryption and audit log, analytics and development tools		
	Rent, Space renovation, conference rooms	Rent, Renovation/Constr	$ 231,980.00
Steelcase	Modular workstations	Equipment	$ 90,000.00
Cisco	Network hardware, secure servers	Equipment	$ 90,000.00
Formlabs	3D printer	Equipment	$ 25,000.00
Crestron	Audio-Visual systems for hybrid rooms	Equipment	$ 25,000.00
Apple/ iPad Pro	Clinical Simulation tablets	Equipment	$ 10,000.00
	Design & prototyping software	Software License	$ 10,000.00
	Contingency (3%)	Equipment	$ 18,000.00
Total FY27 Expenditure			$ 619,980.00

Vendor	Equipment / Item Description	Category (See Category Options)	FY28 Estimated Cost
Azure, AWS, Databricks	Approximately 30 secure computational workspaces to sup	Secure research data en	$ 150,000.00
	Rent	Rent, Renovation/Constr	$ 190,000.00
Cisco	Expansion of secure IT infrastructure & servers	Equipment	$ 200,000.00

New Technologies	Additional 3D printers/ Lasers etc	Equipment	$ 300,000.00
MDClone, or equivalent synthetic d	A synthetic health data platform enabling cohort creation, f	A synthetic data paltform	$ 400,000.00
Dell Technologies, NVIDIA.	Enables training, testing, and optimization of imaging mode	AI Compute Infrastructur	$ 260,000.00
Medable, Castor, Florence, RedCa	An FDA aligned system supporting protocol management, e	Digital trails and piolt ma	$ 150,000.00
Cisco, Logitech Medical.	Secure medical grade telemedicine stations, high-quality c	Telehealth and remote ec	$ 90,000.00
	Contingency (3%)	Equipment	$ 52,000.00
Total FY28 Expenditure			$ 1,792,000.00

Vendor	Equipment/Item Description	Category (See Category Options)	FY29 Estimated Cost
SimX / CAE Healthcare	Tools to simulate clinical workflows, run human-factors ass	Clinical Simulation & Usa	$ 120,000.00
Sony Medical, Butterfly iQ+.	Allows imaging-AI companies to run initial feasibility tests a	Light Imaging Equipment	$ 23,000.00
Crestron, Logitech Rally.	High end audio/video systems supporting real-time bi-natic	Advanced AV Collaborati	$ 60,000.00
Cisco, Palo Alto Networks	network security upgrades, advanced encryption module, a	HIPAA (Phase 2)	$ 50,000.00
	Rent	Rent, Renovation/Constr	$ 200,000.00
AWS	Cloud credit for clinical trails	Software License	$ 60,000.00
Crestron	AV maintenance + calibration	Equipment	$ 20,000.00
	Contingency	Equipment	$ 16,000.00
		*We are currently in the process of collecting p	
Total FY29 Expenditure	or infrastructures previously established within the ARC net	##################	$ 549,000.00

rice quotes and have not yet selected vendors or finalized any commitn